Young, Matthew B.
Norrholm, Seth D.
Khoury, Lara M.
Jovanovic, Tanja
Rauch, Sheila A.M.
Reiff, Collin M.
Dunlop, Boadie W.
Rothbaum, Barbara O.
Howell, Leonard L.
Funding for this research was provided by:
National Institute on Drug Abuse (K05 DA031246)
National Institute of General Medical Sciences (K21 GM000680)
Article History
Received: 23 March 2017
Accepted: 24 June 2017
First Online: 24 July 2017
Compliance with ethical standards
: Studies were in accordance with National Institutes of Health guidelines, and all procedures were approved by the Institutional Animal Care and Use Committee at Emory University.
: M.B.Y. became employed by Shire Pharmaceuticals (Lexington, MA, USA) after completion of the studies described herein. M.B.Y. was supported by a NIH/NIGMS IRACDA grant K21 GM000680 awarded to Emory University. L.L.H. was supported by NIH/NIDA K05 DA031246. B.O.R. has funding from Wounded Warrior Project, Department of Defense Clinical Trial Grant No. W81XWH-10-1-1045, “Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with a Cognitive Enhancer,” National Institute of Mental Health Grant No. 1R01MH094757-01, “Prospective Determination of Psychobiological Risk Factors for Posttraumatic Stress,” Brain and Behavior Research Foundation (NARSAD) Distinguished Investigator Grant, “Optimal Dose of early intervention to prevent PTSD,” and McCormick Foundation “Brave Heart: MLB’s Welcome Back Veterans SouthEast Initiative.” Dr. Rothbaum receives royalties from Oxford University Press, Guilford, APPI, and Emory University and received one advisory board payment from Genentech. B.W.D. has received research support from Assurex, Axsome, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, NIMH, Otsuka, Pfizer, and Takeda. He has served as a consultant to Pfizer and Medavante.
: The authors declare that they have no conflict of interest.